RxDoctor Payments Data

Zahir Osuna, MD

Internal Medicine · San Antonio, TXNPI 1568968147

Payments from drug & device makers

$2,211in general payments, 2019–2025

Across 82 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$809
  • Lilly USA, LLC$519
  • Bayer$169
  • Dexcom, Inc.$125
  • Boehringer Ingelheim$119
  • AbbVie$118
  • plus $353 from 11 others

What the payments were for

  • Food & beverage$2,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,211 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$36,656
Medicare patients
113
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide223$249,220
JardianceEmpagliflozin156$249,187
JanuviaSitagliptin Phosphate153$227,246
RybelsusSemaglutide52$133,620
EliquisApixaban116$110,527
TrulicityDulaglutide49$81,787
MounjaroTirzepatide61$67,282
FarxigaDapagliflozin Propanediol53$60,497
Janumet XrSitagliptin Phos/Metformin Hcl32$40,329
Bydureon BciseExenatide Microspheres21$35,250
MyrbetriqMirabegron29$33,114
XifaxanRifaximin15$29,906
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$28,454
VraylarCariprazine Hcl15$22,963
Repatha SureclickEvolocumab22$22,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$809$382,840275 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$119$276,060182 claims
Lilly USA, LLCTrulicity, Mounjaro$519$149,069110 claims
PfizerEliquis$19$110,527116 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$73$71,94276 claims
AbbVieVraylar, Linzess$118$36,72832 claims
Astellas Pharma US IncMyrbetriq$18$33,11429 claims
Johnson & JohnsonXarelto$51$20,28717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →